Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability; and to define the maximum
tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and
tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and
when given in combination with zanubrutinib.